Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 4OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

pembrolizumab 9Drug Therapy 9Bevacizumab 9Radiotherapy 8Carboplatin 8Oxaliplatin 7Cyclophosphamide 7Surgical Procedures, Operative 6Cisplatin 6Capecitabine 6tislelizumab 5Paclitaxel 5Fluorouracil 5Docetaxel 5Control Groups 5Nivolumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3fludarabine 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡